Tag Archives: Jonathan Chang

Athenex (ATNX) Gets a Hold Rating from Leerink Partners

Leerink Partners analyst Jonathan Chang maintained a Hold rating on Athenex (ATNX – Research Report) on July 6. The company’s shares closed last Wednesday at $4.03, close to its 52-week low of $3.66. According to TipRanks.com, Chang is a 4-star

Revolution Medicines (RVMD) Receives a Buy from Leerink Partners

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on June 17. The company’s shares closed last Friday at $33.96. According to TipRanks.com, Chang is a 4-star analyst with an average return of

Leerink Partners Keeps Their Hold Rating on Adaptimmune Therapeutics (ADAP)

In a report issued on May 20, Jonathan Chang from Leerink Partners maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report). The company’s shares closed last Friday at $5.09, close to its 52-week low of $3.79. According to

Immatics (IMTX) Gets a Buy Rating from Leerink Partners

In a report issued on May 18, Jonathan Chang from Leerink Partners reiterated a Buy rating on Immatics (IMTX – Research Report), with a price target of $26.00. The company’s shares closed last Friday at $11.30. According to TipRanks.com, Chang

Xencor (XNCR) Initiated with a Buy at Leerink Partners

Xencor (XNCR – Research Report) received a Buy rating and a $57.00 price target from Leerink Partners analyst Jonathan Chang on May 5. The company’s shares closed last Friday at $39.61. According to TipRanks.com, Chang is a 4-star analyst with

Leerink Partners Keeps a Hold Rating on Athenex (ATNX)

Leerink Partners analyst Jonathan Chang maintained a Hold rating on Athenex (ATNX – Research Report) on May 5. The company’s shares closed last Friday at $4.60, close to its 52-week low of $3.66. According to TipRanks.com, Chang is a 4-star